Moderna’s mRNA Flu Shot FDA Progress Sparks 9% Stock Surge

BTCC / BTCC Square / Global Cryptocurrency /

Author:

Release Time:

2026-06-17 02:22:03

BTCCSquare news:

Moderna (MRNA) shares surged 9.1% after FDA reviewers found no major deficiencies in its mFlusiva vaccine application. The VRBPAC committee will vote June 18 on approval for adults 50+, with a decision expected by August 5. This marks a potential first-mover advantage for mRNA-based flu vaccines in the U.S. market.

The biotech firm simultaneously announced leadership changes, appointing Ester Banque as Chief Commercial Officer ahead of planned 2027-2028 product launches. This regulatory milestone demonstrates how breakthrough medical technologies can create immediate market value—a dynamic familiar to crypto investors watching FDA decisions impact related biotech tokens.

By:

Log in to Reply

SpaceX Leads FAB10 Surge with Record Valuation and AI Acquisition

Articles on this site are sourced from public networks or curated by AI for informational purposes only and do not represent BTCC’s views. Original rights belong to the respective authors. For copyright concerns, please contact [email protected]. BTCC assumes no liability for the accuracy, timeliness, or completeness of this information, and disclaims all liability arising from reliance on such content. This content is for reference only and should not be taken as investment, legal, or commercial advice.